Background {#Sec1}
==========

Spinal anaesthesia is widely used for various surgical procedures. During spinal anaesthesia, sedation is frequently employed to relieve perioperative anxiety \[[@CR1]\]. Recently, dexmedetomidine has become popular as a sedative agent, as it causes less respiratory depression compared to other commonly used agents, such as propofol and benzodiazepines \[[@CR2], [@CR3]\].

Bradycardia is a complication of spinal anaesthesia \[[@CR4]\], and the incidence of bradycardia is high when dexmedetomidine is administered as a sedative during spinal anaesthesia \[[@CR3], [@CR5]--[@CR7]\]. Treatment of bradycardia in this case includes decreasing the dose or stopping the administration of dexmedetomidine and/or administering intravenous atropine. Although sedatives such as clonidine and propofol used during spinal anaesthesia attenuate an increase in heart rate (HR) by intravenous atropine \[[@CR8], [@CR9]\], to the best of our knowledge, there have been no studies evaluating the HR response of intravenous atropine to bradycardia in patients receiving dexmedetomidine during spinal anaesthesia. We investigated the effect of dexmedetomidine administration on the positive chronotropic effect of atropine for treating bradycardia during spinal anaesthesia by conducting a retrospective analysis.

Methods {#Sec2}
=======

This study was approved by the Hikone Municipal Hospital Ethical Review Board (approval number: 28-4, 17 Nov 2016). The requirement for an informed consent from each individual was waived by the review board because of the retrospective nature of the study.

We retrospectively analysed the anaesthesia records of 137 patients who developed bradycardia during spinal anaesthesia for transurethral, perineal, and lower limb surgeries from 2012 to 2015 at Hikone Municipal Hospital. Patients \< 20 years; those with arrhythmias, implantable pacemakers, pregnancies, spinal cord injuries, and preoperative treatment with beta antagonists; and those undergoing surgeries requiring levels of spinal anaesthesia higher than T4 (such as appendectomy \[[@CR10]\]) were excluded. Bradycardia was defined as a decrease of HR \< 50 bpm or a decrease by more than 30 bpm from the baseline HR before anaesthesia. Spinal anaesthesia was administered after lumbar puncture in the lateral decubitus position with a 25-gauge Quincke needle in the midline between the L4 and L5 or the L3 and L4 levels. Sensory level, defined as the loss of cold sensation to ice, was assessed 15 min after spinal anaesthesia in a supine position.

Patients received either intravenous dexmedetomidine (D group), propofol (P group), or neither (nonDnonP group) for sedation. Dexmedetomidine was administered at 0.6 μg/kg/h following a loading dose of 6.0 μg/kg/h for 10 min. Propofol was administered at 2.5--4.0 mg/kg/h. The propofol concentration (μg/ml) was calculated using the Schnider pharmacokinetic model \[[@CR11]\]. Patients received intravenous atropine 0.5 mg without changing the infusion rate of the sedatives after the development of bradycardia.

Statistical analysis {#Sec3}
--------------------

The continuous variables were expressed as the median (interquartile range), and the Kruskal-Wallis test was used for analysis. Categorical data were expressed as the number of patients and were compared using the chi-square test. Changes in heart rate between the groups were compared using a two-factor analysis of variance. Univariate and multivariable linear regression analyses were performed to analyse the change in heart rate as a dependent variable and the presence or absence of each sedative as an independent variable. In the multivariable analysis, age and sensory block level were also included as independent variables. In order to evaluate the concentration of propofol, we also performed another linear regression analysis with propofol concentration as independent variable. Because dexmedetomidine was administered constantly, it was examined as a binominal variable. Partial regression coefficients and 95% confidence intervals (95% CI) were calculated and were considered significant if *p* \<  0.05. For multiple comparisons, *p* \< 0.025 was used as the significance level using Bonferroni's method. Statistical analysis was performed using IBM SPSS Statistics Version 22 (IBM Japan, Tokyo, Japan).

Results {#Sec4}
=======

Patient characteristics {#Sec5}
-----------------------

A total of 137 patients were considered for the study. Of these, 108 patients were included and 29 patients were excluded (patients on ephedrine or nicardipine, *n* = 20; patients on β-blockers, *n* = 4; patients with arrhythmias, *n* = 2; patients with pacemakers, *n* = 1; surgeries requiring high spinal block level, *n* = 1; patients with a history of spinal cord injury, *n* = 1).

The number of patients receiving transurethral, perineal, and lower limb surgery was 33, 28, and 47, respectively. Although there was a significant difference in age, there were no significant differences with regard to sex, body weight, and sensory block level among the three groups (age, *p* = 0.033; sex, *p* = 0.114; weight, *p* = 0.151; sensory block level, *p* = 0.105) (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristicsAllnonDnonPD*Pn*108146925Age71 \[51--78\]83 \[65--87\]70 \[53--75\]67 \[35--79\]Sex (M/F)70/386/849/2015/10Weight (kg)60.0 \[49.0--69.0\]52.0 \[47.5--63.5\]62.0 \[49.5--72.0\]57.0 \[50.5--64.5\]Sensory block level6 \[6--8\]5 \[4--6\]6 \[6--9\]7 \[6--10\]Values are expressed as median \[interquartile range\] or number of patients*bpm* beats per minute, *D* dexmedetomidine group, *P* propofol group, *nonDnonP* non-dexmedetomidine-non-propofol group, *sensory block level* thoracic segments

Changes in heart rate after atropine administration {#Sec6}
---------------------------------------------------

There were no significant differences in the heart rate among the three groups before atropine administration.

Heart rate was significantly slower in the D group compared with the nonDnonP group 5 to 60 min after administration of atropine (5 min, *p* = 0.002; 10 min, *p* \< 0.001; 15 min, *p* = 0.016; 20 min, *p* = 0.009; 30 min, *p* = 0.001; 60 min, *p* \< 0.001). Heart rate was significantly slower in the P group compared with the nonDnonP group only at 60 min after administration of atropine (*p* = 0.002) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Heart rate after administration of atropine in the dexmedetomidine, propofol, and non-dexmedetomidine-non-propofol groups. Values are expressed as the mean ± SD. \**p* \< 0.025 (compared with the nonDnonP group). D, dexmedetomidine; nonDnonP, non dexmedetomidine-non propofol; P, propofol; SD, standard deviation

Therefore, comparison among three groups was made based on the degree of increase in heart rate. The graphs showing the change in heart rate in each group (Δ heart rate) are shown in Fig. [2](#Fig2){ref-type="fig"}. The increase in heart rate was significantly lower in the D group compared with the nonDnonP group 5, 10, 20, 30, and 60 min after administration of atropine (5 min, *p* = 0.002; 10 min, *p* = 0.001; 20 min, *p* = 0.017; 30 min, *p* = 0.004; 60 min, *p* \< 0.001). The increase in heart rate was significantly lower in the P group only at 60 min after atropine administration (*p* = 0.005).Fig. 2Increase in heart rate after administration of atropine in the dexmedetomidine, propofol, and non-dexmedetomidine-non-propofol groups. Values are expressed as the mean ± SD. \**p* \< 0.025 (compared with the nonDnonP group). D, dexmedetomidine; nonDnonP, non dexmedetomidine-non propofol; P, propofol; SD, standard deviation

Regression analysis of heart rate response {#Sec7}
------------------------------------------

Heart rate response was significantly smaller in the D group than in the nonDnonP group at 5, 30, and 60 min after atropine administration as determined by univariate analysis (5 min, *B* (partial regression coefficient) − 6.659, 95% CI − 10.830\~− 2.489, *p* = 0.002; 30 min, *B* − 7.002, 95% CI − 11.749\~− 2.255, *p* = 0.004; 60 min, *B* 9.160, 95% CI − 13.249\~− 5.071, *p* \< 0.001). It was also significantly smaller in the P group compared to the nonDnonP group at 60 min as determined by univariate analysis (*B* − 6.670, 95% CI − 11.292\~− 2.048, *p* = 0.005). Moreover, multivariable analysis adjusted for age and sensory block level as independent variables did not greatly affect the *p* values of the D group analysed using univariate analysis.

The results of the univariate and multivariable analyses with propofol concentration as the independent variables are shown in Table [2](#Tab2){ref-type="table"}.Table 2Univariate and multivariable analyses of heart rateUnivariate analysisMultivariable analysis*B*95% CI*p* value*B*95% CI*p* valuePost 5 D used− 6.284− 9.969 to − 2.5990.001− 7.160− 12.626 to − 1.6940.011 P concentration− 2.526− 5.960 to 0.9090.148− 4.011− 8.870 to 0.8480.104 Age0.051− 0.020 to 0.1220.155− 0.006− 0.098 to 0.0860.900 Level0.329− 0.397 to 1.0560.3680.486− 0.238 to 1.2100.184Post 30 D used− 5.731− 9.938 to − 1.5250.008− 7.487− 14.128 to − 0.8460.028 P concentration− 3.314− 7.265 to 0.6370.099− 5.033− 10.950 to 0.8850.094 Age− 0.016− 0.095 to 0.0640.697− 0.120− 0.232 to − 0.0080.037 Level0.111− 0.790 to 1.0130.8050.122− 0.757 to 1.0010.782Post 60 D used− 8.611− 12.152 to − 5.069\< 0.001− 10.205− 15.787 to − 4.6240.001 P concentration− 5.491− 8.750 to − 2.2320.001− 6.149− 10.952 to − 1.3460.013 Age0.010− 0.061 to 0.0820.772− 0.030− 0.121 to 0.0610.507 Level0.067− 0.723 to 0.8570.8650.169− 0.561 to 0.9000.643*B* partial regression coefficient, *CI* confidence interval, *D* dexmedetomidine, *P concentration* propofol concentration (μg/ml), *Level* sensory block level

The multivariable analysis indicated that the use of dexmedetomidine attenuated the increase of HR by 7, 7, and 10 bpm at 5, 30, and 60 min, respectively, after atropine administration.

Discussion {#Sec8}
==========

Although this study was a retrospective one, we observed that the positive chronotropic effect of atropine administered in response to bradycardia during spinal anaesthesia was significantly attenuated in the D group compared to the nonDnonP group (as measured at 5, 30, and 60 min after atropine administration). This may have been previously known empirically. However, to the best of our knowledge, this is the first report of the attenuation of the positive chronotropic effect of intravenous atropine on bradycardia by dexmedetomidine during spinal anaesthesia.

Other studies have shown that there were no significant differences in heart rate between groups receiving and those not receiving atropine simultaneously during sedation with dexmedetomidine under spinal anaesthesia \[[@CR12]\]. Although the conditions for the use of atropine were different from those of our study, the findings previously reported may support our results that indicated that dexmedetomidine attenuates the positive chronotropic effect of intravenous atropine to bradycardia during spinal anaesthesia.

The attenuation of the increase in heart rate response to atropine may be due to sympathetic inhibition by dexmedetomidine. Dexmedetomidine has sedative and analgesic effects because of its agonist activity on alpha-2 adrenergic receptors. It also diminishes the release of norepinephrine and inhibits sympathetic activity, thereby decreasing heart rate and blood pressure \[[@CR13], [@CR14]\]. Propofol has been reported to attenuate the ability of atropine to increase heart rate. Horiguchi et al. suggested that this was due to the suppression of the autonomic nervous system, particularly the sympathetic component \[[@CR9]\]. Dexmedetomidine administration also causes bradycardia via central sympathetic suppression in a manner similar to propofol.

Oral administration of clonidine, another α2 adrenergic receptor agonist, was also reported to attenuate the heart rate response to intravenous atropine \[[@CR8]\]. Compared to clonidine, dexmedetomidine has approximately eight times higher α2 selectivity. Therefore, the sympathetic blockade effect is stronger, and the attenuation of the effect of atropine is believed to be more powerful.

There are several limitations to our study. First, this was a single-centre, retrospective analysis. Second, all subjects were of Asian descent; therefore, possible racial differences could not be considered. Third, running fluid infusion was performed after atropine administration, which may have resulted in the administration of dexmedetomidine or propofol bolus, which may have affected the heart rate. Fourth, our sample size was small; the sufficient number of subjects may change the results of the investigation.

Although one of the first steps in the treatment of dexmedetomidine-induced bradycardia is to stop the drug infusion, the half-life of dexmedetomidine is as long as 130 min and bradycardia may persist into the postoperative period. Therefore, there is a possibility that the positive chronotropic effect of atropine may also have been attenuated for a similar duration of time \[[@CR15]\]. Considering the mechanism of bradycardia, the administration of sympathomimetic drugs may be effective in improving the bradycardia occurring due to dexmedetomidine during spinal anaesthesia \[[@CR14]\]. We analysed and compared a small group of patients in whom ephedrine was administered for the bradycardia to patients administered atropine. Although the sample size was too small to include in this study, the use of ephedrine, frequently used as a sympathomimetic drug, significantly increased the heart rate 5 min after administration (Δ heart rate, ephedrine 18 ± 6 bpm, atropine 4 ± 5 bpm, *p* \< 0.001). We compared heart rate only at the 5 min time point, as it is reported that the maximum effect of ephedrine occurs in about 4 min \[[@CR16]\]. Increasing the dosage of atropine may also be effective in increasing heart rate. Lim et al. compared the use of a 5- versus 10-μg/kg dose of atropine to treat bradycardia during spinal anaesthesia and reported that the increase in heart rate was higher in the 10 μg/kg group \[[@CR17]\]. In our study, the median atropine dose in each group was 7--8 μg/kg. The increase in heart rate may have been greater with a higher dose. However, there are reports that the improvement in bradycardia was not optimal even when the dose of atropine was increased in the clonidine pretreatment group \[[@CR8]\]. Further investigation is necessary.

Conclusions {#Sec9}
===========

The positive chronotropic effects of atropine might be attenuated with the use of dexmedetomidine or propofol during spinal anaesthesia. Although atropine may be administered when bradycardia occurs, a dose of atropine might result in an insufficient effect against the bradycardia. The sufficient number of subjects may change the results of the investigation, and large-scale randomised controlled trials will be necessary.
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